Vancouver, B.C. and Boston, MA, July 20, 2016 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announced today that the process of retrofitting and requalifying components to optimize the patented design of the i/Blue Imaging System is on schedule. As previously announced, the i/Blue Alpha Prototype A was successfully moved from Lawrence Livermore National Lab to the University of Rochester Laboratory for Laser Energetics where Dr. Stavros Demos, the inventor of the technology, continues to assist the Imagin team with the development of the Alpha Prototype B.
Three key components that will differentiate this instrument in the market place are being requalified, including fiber optic cables, specialty cameras and the required processing software, all of which have been defined and in process to be integrated into the Alpha Prototype B. The new cable connecting the cystoscope to the i/Blue systems will contain over 335,000 fibers, more than double the fiber count of the original prototype. The camera being used is the highest light sensitive scientific model available. The software required to integrate all the components is being developed by Dr. Ronald Wood, whose services have been added to the contract with of the University of Rochester Medical Center. Dr. Wood has solid experience in this area and has conducted previous bladder studies. The Company believes the project is on schedule for year-end 2016.
“We have developed a positive relationship with the University of Rochester Medical Center and the Laboratory for Laser Energetics and we’re excited to work with them to facilitate Imagin’s success,” said Mike Vergano, Imagin’s Director of Engineering and Operations.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect
cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imagindev.wpengine.com.
ON BEHALF OF THE BOARD:
President & CEO
For further information, contact:
Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: [email protected]
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.